scholarly journals Risk Factors of Portal Vein Thrombosis after Devascularization Treatment in Patients with Liver Cirrhosis: A Nested Case-Control Study

2020 ◽  
Vol 2020 ◽  
pp. 1-11
Author(s):  
Shenxin Lu ◽  
Guohua Hu ◽  
Shiyao Chen ◽  
Jian Wang

Background and Aim. To investigate the incidence of portal vein thrombosis (PVT) after devascularization treatment and to explore the risk factors of perioperative PVT and PVT diagnosed during the follow-up period after surgery. Methods. We retrospectively reviewed medical records from cirrhosis patients who underwent devascularization for the treatment of portal hypertension in our hospital between January 1, 2008, and December 20, 2014. Patients were followed up to investigate the PVT incidence at different times after surgery. Patients were divided into two groups (PVT, no PVT), and the risk factors for PVT after surgery were determined. Results. Until October 16, 2015, the median follow-up time of the 124 patients enrolled into this study was 41.43 months (range, 5.47–95.30 months). 61 patients had perioperative PVT, and 21 (16.94%) patients had PVT diagnosed during the follow-up period. Those who had lower preoperative white blood cell counts, larger preoperative portal vein trunk diameter, and no gastric varices were more likely to have perioperative thrombosis. In those without perioperative PVT, a history of hypertension, higher grade of splenomegaly, and higher preoperative levels of creatinine were independent predictors of PVT occurrence during the follow-up period. Conclusions. The risk factors for perioperative PVT in cirrhotic patients after devascularization were lower preoperative white blood cell count and larger portal vein trunk diameter, with no gastric varices. A history of hypertension, a larger spleen, and higher preoperative creatinine level are independent predictors of PVT during follow-up after surgery in patients without perioperative PVT.

2020 ◽  
Vol 46 (06) ◽  
pp. 673-681 ◽  
Author(s):  
Oana Nicoară-Farcău ◽  
Guillem Soy ◽  
Marta Magaz ◽  
Anna Baiges ◽  
Fanny Turon ◽  
...  

AbstractPortal vein thrombosis (PVT) is a frequent event in patients with cirrhosis regardless of etiology. Notwithstanding the commonality of the problem, the pathophysiology and risk factors for PVT in cirrhosis are largely unknown. The clinical impact of PVT in the natural history of cirrhosis is unclear, indications for PVT treatment are not well defined, and treatment recommendations are based on experts' opinion and consensus only. Therefore, this review aims to summarize current knowledge of mechanisms and risk factors for PVT development and assess the current evidence of PVT management, with a special focus on strategies of anticoagulation and transjugular intrahepatic portosystemic shunt placement.


Author(s):  
Lorena Reyes ◽  
José Ignacio Herrero ◽  
Fernando Rotellar Sastre ◽  
José Antonio Páramo

Digestion ◽  
2008 ◽  
Vol 78 (2-3) ◽  
pp. 139-143 ◽  
Author(s):  
Chen-Jung Chang ◽  
Yih-Tsong Shiau ◽  
Te-Li Chen ◽  
Ming-Chih Hou ◽  
Chih-Hao Sun ◽  
...  

2008 ◽  
Vol 99 (04) ◽  
pp. 675-682 ◽  
Author(s):  
Matteo Galli ◽  
Monica Gianni ◽  
Walter Ageno ◽  
Francesco Dentali

SummaryInherited thrombophilic abnormalities may have a role in the development of portal vein thrombosis (PVT).However, the prevalence of these factors in patients with PVT has been evaluated only in small studies with non-conclusive results. It was the purpose of this study to assess the risk of PVT associated with factorV Leiden (FVL) and G20210A prothrombin mutation (PTM). The MEDLINE, EMBASE, Cochrane Library databases, reference lists of retrieved articles and contact with content experts were used. Studies carried out in Western Europe comparing the prevalence of prothrombotic abnormalities in patients with PVT and in controls without a history of thromboembolic disease were included. Two reviewers independently selected studies and extracted study characteristics, quality and outcomes. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for each trial and pooled using a fixed and random-effects model. Statistical heterogeneity was evaluated using the I2 statistic. Sensitivity analyses were performed examining separately studies according to the etiology of PVT and to control population. Twelve studies involving more than 3,000 patients were included. The pooled OR for PVT was 1.90 (95%CI: 1.25, 2.90) in patients with FVL and 4.48 (95%CI: 3.10, 6.48) in patients with PTM. In conclusion, PVT is associated with the presence of FVL and PTM in Western Europe.


Sign in / Sign up

Export Citation Format

Share Document